SWX:NOVNPharmaceuticals
How Novartis' Alzheimer’s Antibody Deal And US Radioligand Expansion At Novartis (SWX:NOVN) Has Changed Its Investment Story
In recent days, Novartis and SciNeuro Pharmaceuticals announced a worldwide licensing and collaboration deal to develop an amyloid beta antibody program for Alzheimer’s disease, while Novartis also unveiled plans for a new radioligand therapy manufacturing facility in Winter Park, Florida, as part of its multi-billion-dollar US investment.
Together, these moves highlight how Novartis is pairing early-stage neuroscience innovation with expanded US radioligand production to deepen its...